The Industry-Dedicated Forum, Focused on Novel Inflammasome Therapeutics
The 4th Inflammasome Therapeutics Summit is the only industry-led forum for large pharma biotech and academic KOLs, with the common goal of accelerating the practical translation and clinical development of inflammasome-targeted drugs that are shaking up the immunology R&D landscape.
As the space eagerly awaits data readouts from proof-of-concept trials and with more companies than ever before, with active inflammasome therapeutic pipelines, this is your opportunity to propel the next frontier of inflammasome therapeutics from pipeline development into a clinical and commercial reality.
Explore the realm of NLRP3 targeting and its advancements, and updates with Novartis, Roche, Ventus, and NodThera
Improve your drug development rationale and disease selection depending on your intervention with Adiso Therapeutics, BioAge Labs, and more
Understand the exciting developments in inflammasome biology and overcoming challenges of preclinical models with from leaders including Takeda and Roche
Progress in biomarker understanding and clinical relevance in-humans with EpicentRx and University of Miami
Optimize the move into the clinic with trial design, patient selection and rational endpoints; and hear from C-level of the hottest biotechs the latest insight into overcoming challenges and progressing in this field including sessions from Ventus, NodThera, and more
Revolutionize the next frontier and discover all the exciting progress beyond NLRP3
Hear about NLRP1, NLRP6, GSDM, AIM, ASC, and more with Harvard University, Washington University, Memorial Sloan Kettering Cancer Center, and more